American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction Article

Visvanathan, Kala, Chlebowski, Rowan T, Hurley, Patricia et al. (2009). American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction . JOURNAL OF CLINICAL ONCOLOGY, 27(19), 3235-3258. 10.1200/JCO.2008.20.5179

Open Access International Collaboration

cited authors

  • Visvanathan, Kala; Chlebowski, Rowan T; Hurley, Patricia; Col, Nananda F; Ropka, Mary; Collyar, Deborah; Morrow, Monica; Runowicz, Carolyn; Pritchard, Kathleen I; Hagerty, Karen; Arun, Banu; Garber, Judy; Vogel, Victor G; Wade, James L; Brown, Powel; Cuzick, Jack; Kramer, Barnett S; Lippman, Scott M

sustainable development goals

authors

publication date

  • July 1, 2009

published in

keywords

  • BONE-MINERAL DENSITY
  • COGNITIVE FUNCTION
  • CONTINUING OUTCOMES RELEVANT
  • ESTROGEN-RECEPTOR
  • ITALIAN RANDOMIZED-TRIAL
  • LOW-DOSE TAMOXIFEN
  • Life Sciences & Biomedicine
  • Oncology
  • POSTMENOPAUSAL WOMEN
  • QUALITY-OF-LIFE
  • SURGICAL ADJUVANT BREAST
  • Science & Technology
  • TECHNOLOGY-ASSESSMENT

Digital Object Identifier (DOI)

publisher

  • AMER SOC CLINICAL ONCOLOGY

start page

  • 3235

end page

  • 3258

volume

  • 27

issue

  • 19